IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA

The 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5–8, 2011 in San Diego, CA. The meeting drew ~800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics session comprised five sessions: (1)Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.

[1]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[2]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[3]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[5]  N. Ajubi,et al.  nmb, a novel gene, is expressed in low‐metastatic human melanoma cell lines and xenografts , 1995, International journal of cancer.

[6]  C. Mackay,et al.  Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. , 1996, Gastroenterology.

[7]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[8]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[9]  J. Marks,et al.  Toward selection of internalizing antibodies from phage libraries. , 1999, Biochemical and biophysical research communications.

[10]  H. Katinger,et al.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.

[11]  S. Atwell,et al.  Selection for improved subtiligases by phage display. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[13]  G. Garcı́a-Cardeña,et al.  Oligomerization-Dependent Regulation of Motility and Morphogenesis by the Collagen Xviii Nc1/Endostatin Domain , 2001, The Journal of cell biology.

[14]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[15]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[16]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[17]  S. Hunt.  Technology evaluation: IMC-1C11, ImClone Systems. , 2001, Current opinion in molecular therapeutics.

[18]  Janice M. Reichert,et al.  Monoclonal antibodies in the clinic , 2001, Nature Biotechnology.

[19]  P. Schirmacher,et al.  The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells , 2001, Oncogene.

[20]  Sun Park,et al.  PRODUCTION AND CHARACTERIZATION OF AN ANTI-IDIOTYPIC SINGLE CHAIN FV THAT RECOGNIZES AN ANTI-DNA ANTIBODY , 2002, Immunological investigations.

[21]  J. Kemp,et al.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis , 2002, Nature.

[22]  Philip R. Johnson,et al.  Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer , 2002, Journal of Virology.

[23]  A. Casadevall,et al.  Isotype Can Affect the Fine Specificity of an Antibody for a Polysaccharide Antigen1 , 2002, The Journal of Immunology.

[24]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Tanha,et al.  Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endothelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  L. Zardi,et al.  Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.

[27]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[28]  Sandor Vajda,et al.  CAPRI: A Critical Assessment of PRedicted Interactions , 2003, Proteins.

[29]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[30]  P. Piedra,et al.  Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. , 2003, Vaccine.

[31]  K. Garcia,et al.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. , 2003, Science.

[32]  B. Goud,et al.  Recombinant Antibodies Against Subcellular Fractions Used to Track Endogenous Golgi Protein Dynamics in Vivo , 2003, Traffic.

[33]  T. Ng,et al.  A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  M. Cragg,et al.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.

[35]  B. Goud,et al.  Recombinant Antibodies to the Small GTPase Rab6 as Conformation Sensors , 2003, Science.

[36]  M. Cragg,et al.  CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. , 2003, Cancer research.

[37]  K. Garcia,et al.  Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex , 2003, Science.

[38]  G. Schuurhuis,et al.  C-Type Lectin-Like Molecule-1 , 2004, Cancer Research.

[39]  P. Parren,et al.  Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy , 2004, The Journal of Immunology.

[40]  K Dane Wittrup,et al.  Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* , 2004, Journal of Biological Chemistry.

[41]  R. Parks,et al.  Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  Christoph E. Dumelin,et al.  Encoded self-assembling chemical libraries , 2004, Nature Biotechnology.

[43]  S. Ramakrishnan,et al.  Improved biological activity of a mutant endostatin containing a single amino-acid substitution , 2004, British Journal of Cancer.

[44]  C. Eigenbrot,et al.  High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. , 2004, Journal of molecular biology.

[45]  L. Dinkelborg,et al.  Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate , 2005, Clinical Cancer Research.

[46]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[47]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[48]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[49]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[50]  J. Marsh,et al.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Casadevall,et al.  Variable-Region-Identical Antibodies Differing in Isotype Demonstrate Differences in Fine Specificity and Idiotype1 , 2005, The Journal of Immunology.

[52]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[53]  H. Katinger,et al.  Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1 , 2005, Journal of Virology.

[54]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[55]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[56]  F. Thistlethwaite,et al.  Engineering T cells for cancer therapy , 2005, British Journal of Cancer.

[57]  A. Ullrich,et al.  Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies , 2005, International journal of cancer.

[58]  Damon L. Meyer,et al.  CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[60]  P. Hawkins,et al.  Drug Insight: emerging therapies for amyloidosis , 2006, Nature Clinical Practice Nephrology.

[61]  John W. Park,et al.  Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.

[62]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[63]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[64]  J. Sprent,et al.  Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease , 2006, Expert opinion on biological therapy.

[65]  Jeong-Sun Kim,et al.  Heavy and Light Chain Variable Single Domains of an Anti-DNA Binding Antibody Hydrolyze Both Double- and Single-stranded DNAs without Sequence Specificity* , 2006, Journal of Biological Chemistry.

[66]  Bali Pulendran,et al.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity , 2006, The Journal of experimental medicine.

[67]  F. Bootz,et al.  Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis , 2007, Arthritis research & therapy.

[68]  R. Karron,et al.  The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. , 2007, Vaccine.

[69]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[70]  A. Villa,et al.  The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. , 2007, Cancer research.

[71]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[72]  George Georgiou,et al.  Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli , 2007, Nature Biotechnology.

[73]  C. Albanesi,et al.  Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. , 2007, Clinics in dermatology.

[74]  A. Casadevall,et al.  The Immunoglobulin Heavy Chain Constant Region Affects Kinetic and Thermodynamic Parameters of Antibody Variable Region Interactions with Antigen* , 2007, Journal of Biological Chemistry.

[75]  M. Glennie,et al.  Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. , 2007, Blood.

[76]  Chien-Hsing Chang,et al.  The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity , 2007, Clinical Cancer Research.

[77]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[78]  B. Liu,et al.  Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. , 2007, Molecular immunology.

[79]  Lennart Martens,et al.  The minimum information about a proteomics experiment (MIAPE) , 2007, Nature Biotechnology.

[80]  T. Allen,et al.  Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Christian Lovis,et al.  Automatic medical encoding with SNOMED categories , 2008, BMC Medical Informatics Decis. Mak..

[82]  G. Adams,et al.  Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro , 2008, British Journal of Cancer.

[83]  A. Bree,et al.  Interleukin-13 Neutralization by Two Distinct Receptor Blocking Mechanisms Reduces Immunoglobulin E Responses and Lung Inflammation in Cynomolgus Monkeys , 2008, Journal of Pharmacology and Experimental Therapeutics.

[84]  E. Moase,et al.  Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer , 2008, Journal of drug targeting.

[85]  Jeffrey J. Gray,et al.  Conformer selection and induced fit in flexible backbone protein-protein docking using computational and NMR ensembles. , 2008, Journal of molecular biology.

[86]  Bruno Cazin,et al.  Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16 , 2008, British journal of haematology.

[87]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[88]  John W. Park,et al.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. , 2008, Journal of pharmaceutical sciences.

[89]  A. Cohen,et al.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[91]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[92]  M. Shlomchik,et al.  Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. , 2008, Blood.

[93]  R. Redfield,et al.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.

[94]  Franck Perez,et al.  Detection of GTP-Tubulin Conformation in Vivo Reveals a Role for GTP Remnants in Microtubule Rescues , 2008, Science.

[95]  L. Helman,et al.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. , 2008, Cancer research.

[96]  Andreas Plückthun,et al.  Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. , 2008, Journal of molecular biology.

[97]  Sandra Lynch,et al.  An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. , 2008, Journal of molecular biology.

[98]  D. Gilham,et al.  The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B‐cell lymphoma , 2008, British journal of haematology.

[99]  S. Nuttall,et al.  Display scaffolds: protein engineering for novel therapeutics. , 2008, Current opinion in pharmacology.

[100]  John Steel,et al.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies , 2008, Proceedings of the National Academy of Sciences.

[101]  J. Sprent,et al.  In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression , 2009, The Journal of experimental medicine.

[102]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[103]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[104]  B Tolner,et al.  Data standards for minimum information collection for antibody therapy experiments. , 2009, Protein engineering, design & selection : PEDS.

[105]  R. Ober,et al.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. , 2009, Advances in immunology.

[106]  Sandra Lynch,et al.  Developing intrabodies for the therapeutic suppression of neurodegenerative pathology , 2009, Expert opinion on biological therapy.

[107]  M. Cancro,et al.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. , 2009, The Journal of clinical investigation.

[108]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[109]  G. Winter,et al.  Phage-encoded combinatorial chemical libraries based on bicyclic peptides. , 2009, Nature chemical biology.

[110]  G. Adams,et al.  Affinity and avidity in antibody-based tumor targeting. , 2009, Cancer biotherapy & radiopharmaceuticals.

[111]  Frederic A. Fellouse,et al.  Crystal structure of full-length KcsA in its closed conformation , 2009, Proceedings of the National Academy of Sciences.

[112]  Jeffrey J. Gray,et al.  RosettaAntibody: antibody variable region homology modeling server , 2009, Nucleic Acids Res..

[113]  B. Goud,et al.  Direct Selection of Monoclonal Phosphospecific Antibodies without Prior Phosphoamino Acid Mapping* , 2009, The Journal of Biological Chemistry.

[114]  Jan Berka,et al.  Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.

[115]  Huijuan Li,et al.  Pharmacological significance of glycosylation in therapeutic proteins. , 2009, Current opinion in biotechnology.

[116]  Jeffrey J. Gray,et al.  Toward high‐resolution homology modeling of antibody Fv regions and application to antibody–antigen docking , 2009, Proteins.

[117]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[118]  Jeong-Sun Kim,et al.  Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. , 2009, Biochemical and biophysical research communications.

[119]  R. Ober,et al.  Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice , 2009, Proceedings of the National Academy of Sciences.

[120]  D. Miller,et al.  Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.

[121]  Laura A. Sullivan,et al.  Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts , 2009, Molecular Cancer Therapeutics.

[122]  Bryn Nelson.  Data sharing: Empty archives , 2009, Nature.

[123]  Sahana Bose,et al.  Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. , 2009, mAbs.

[124]  F. Bootz,et al.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis , 2009, Arthritis research & therapy.

[125]  P. Parren,et al.  Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage , 2009, The Journal of Immunology.

[126]  J. Zha,et al.  Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis , 2009, Oncogene.

[127]  S. Ram,et al.  Analyses of the Recycling Receptor, FcRn, in Live Cells Reveal Novel Pathways for Lysosomal Delivery , 2009, Traffic.

[128]  S. Dübel,et al.  A multi-Fc-species system for recombinant antibody production , 2009, BMC biotechnology.

[129]  Franklin Peale,et al.  Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.

[130]  R. Egan,et al.  The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.

[131]  P. Kufer,et al.  Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. , 2009, Leukemia research.

[132]  Hulin Jin,et al.  Fully in vitro selection of recombinant antibodies , 2009, Biotechnology journal.

[133]  András Fiser,et al.  Identification of Linear Epitopes in Bacillus anthracis Protective Antigen Bound by Neutralizing Antibodies* , 2009, The Journal of Biological Chemistry.

[134]  Teresa Mitchell,et al.  Production of monoclonal antibodies by glycoengineered Pichia pastoris. , 2009, Journal of biotechnology.

[135]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[136]  A. Lugovskoy,et al.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR , 2009 .

[137]  Benjamin D. Sellers,et al.  Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains. , 2009, Journal of molecular biology.

[138]  J. Zimmer,et al.  Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.

[139]  S. Sidhu,et al.  Two-state selection of conformation-specific antibodies , 2009, Proceedings of the National Academy of Sciences.

[140]  P. Parren,et al.  Functional reconstruction of structurally complex epitopes using CLIPS™ technology , 2009 .

[141]  J. Leonard,et al.  A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma , 2009, British journal of haematology.

[142]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[143]  Y. Kim,et al.  A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity , 2009, Cellular and Molecular Life Sciences.

[144]  P. Patterson,et al.  Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease , 2009, The Journal of Neuroscience.

[145]  Alessandra Villa,et al.  New strategy for the extension of the serum half-life of antibody fragments. , 2009, Bioconjugate chemistry.

[146]  A. Korman,et al.  Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors , 2009, Clinical Cancer Research.

[147]  A. Kossiakoff,et al.  An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells , 2009, Proceedings of the National Academy of Sciences.

[148]  P. Kwong,et al.  Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F , 2010, Journal of Virology.

[149]  Q. Pankhurst,et al.  Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. , 2010, Biomaterials.

[150]  A. Petrie,et al.  Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis , 2010, British journal of haematology.

[151]  Ww Cheng,et al.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment , 2010, Expert opinion on drug delivery.

[152]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  Rajeeva Singh,et al.  Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. , 2010, Bioconjugate chemistry.

[154]  Jeffrey J. Gray,et al.  SnugDock: Paratope Structural Optimization during Antibody-Antigen Docking Compensates for Errors in Antibody Homology Models , 2010, PLoS Comput. Biol..

[155]  Roger Baxter,et al.  Treatment with monoclonal antibodies against Clostridium difficile toxins. , 2010, The New England journal of medicine.

[156]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[157]  T. Logtenberg,et al.  Generation of stable cell clones expressing mixtures of human antibodies , 2010, Biotechnology and bioengineering.

[158]  Murali M. Yallapu,et al.  Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. , 2010, Journal of colloid and interface science.

[159]  H. Hartung,et al.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? , 2010, Archives of neurology.

[160]  Anna M Wu,et al.  Antibody vectors for imaging. , 2010, Seminars in nuclear medicine.

[161]  A. Messer,et al.  Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice , 2010, Journal of neuropathology and experimental neurology.

[162]  P. Moore,et al.  Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.

[163]  P. Moore,et al.  Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. , 2010, Arthritis and rheumatism.

[164]  M. Diamond,et al.  Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.

[165]  C. Fichtenbaum,et al.  Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults , 2010, Antimicrobial Agents and Chemotherapy.

[166]  R. Weimer,et al.  An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies , 2010, Oncogene.

[167]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[168]  K. Garcia,et al.  Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. , 2010, Structure.

[169]  C. Pyke,et al.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.

[170]  James Theiler,et al.  Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains , 2010, Nature Medicine.

[171]  Jeffrey J. Gray,et al.  A generalized approach to sampling backbone conformations with RosettaDock for CAPRI rounds 13–19 , 2010, Proteins.

[172]  James C Paulson,et al.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22. , 2010, Blood.

[173]  F. D. De Braud,et al.  The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. , 2010, European journal of cancer.

[174]  Bette Korber,et al.  Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys , 2010, Nature Medicine.

[175]  R. Rico-Hesse,et al.  Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2 , 2010, Journal of Virology.

[176]  M. Jaggi,et al.  Scope of nanotechnology in ovarian cancer therapeutics , 2010, Journal of ovarian research.

[177]  A. Wu,et al.  ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). , 2010, Protein engineering, design & selection : PEDS.

[178]  B. Liu,et al.  Amyloid-β Immunotherapy for Alzheimers Disease , 2010 .

[179]  C. Daridon,et al.  Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus , 2010, Arthritis research & therapy.

[180]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[181]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[182]  B. Strober,et al.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. , 2010, The New England journal of medicine.

[183]  J. Fargnoli,et al.  Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. , 2010, Cancer research.

[184]  Laura A. Sullivan,et al.  r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction , 2010, PloS one.

[185]  P. Schirmacher,et al.  Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice , 2010, The Journal of experimental medicine.

[186]  Christoph E. Dumelin,et al.  Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library. , 2010, Bioconjugate chemistry.

[187]  A. Petrie,et al.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits , 2010, Nature.

[188]  J. Sprent,et al.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25 , 2010, Proceedings of the National Academy of Sciences.

[189]  P. Kwong,et al.  Structural basis of respiratory syncytial virus neutralization by motavizumab , 2010, Nature Structural &Molecular Biology.

[190]  N. Stambler,et al.  Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. , 2010, The Journal of infectious diseases.

[191]  Suzanne F. Jones,et al.  Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE). , 2010 .

[192]  Kunihiro Hattori,et al.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization , 2010, Nature Biotechnology.

[193]  M. Cragg,et al.  Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. , 2010, Blood.

[194]  P. Hwu,et al.  Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. , 2010 .

[195]  H. Monyer,et al.  Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors , 2010, Nature Methods.

[196]  H. Yagita,et al.  Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. , 2010, Biochemical and biophysical research communications.

[197]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  Benjamin D. Sellers,et al.  Antibodies as a model system for comparative model refinement , 2010, Proteins.

[199]  Jeong-Sun Kim,et al.  Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies , 2009, Nucleic acids research.

[200]  D. Centonze,et al.  Considerations on discontinuing natalizumab for the treatment of multiple sclerosis , 2010, Annals of neurology.

[201]  W. Fridman,et al.  Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. , 2010, Blood.

[202]  Lucy J. Holt,et al.  Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. , 2010, Protein engineering, design & selection : PEDS.

[203]  J. Baselga,et al.  CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. , 2010, Clinical breast cancer.

[204]  Karthik Devarajan,et al.  Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies , 2010, Science Signaling.

[205]  C. J. Hutchings,et al.  Therapeutic antibodies directed at G protein-coupled receptors , 2010, mAbs.

[206]  Katherine E. Talcott,et al.  Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. , 2011, Investigative ophthalmology & visual science.

[207]  John McCafferty,et al.  Beyond natural antibodies: the power of in vitro display technologies , 2011, Nature Biotechnology.

[208]  Colin L Masters,et al.  Crystal Structure of the Amyloid-β p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease , 2011, The Journal of Neuroscience.

[209]  B. Cornelissen,et al.  Therapeutics , Targets , and Chemical Biology Imaging DNA Damage In Vivo Using g H 2 AX-Targeted Immunoconjugates , 2011 .

[210]  Q. Zeng,et al.  Targeting Intracellular Oncoproteins with Antibody Therapy or Vaccination , 2011, Science Translational Medicine.

[211]  Qing-hui Zhou,et al.  Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. , 2011, Molecular pharmaceutics.

[212]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[213]  D. Cox,et al.  Synthetic antibodies designed on natural sequence landscapes. , 2011, Journal of molecular biology.

[214]  Martin C. Wright,et al.  A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor , 2011, mAbs.

[215]  W. Olson,et al.  In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen , 2011, Molecular Cancer Therapeutics.

[216]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[217]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  G. Adams,et al.  Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.

[219]  P. S. Andersen,et al.  Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor , 2011, mAbs.

[220]  J. Bading,et al.  Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging. , 2011, Bioconjugate chemistry.

[221]  CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells , 2011, The Journal of Immunology.

[222]  George A. Williams,et al.  Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration , 2011, Proceedings of the National Academy of Sciences.

[223]  L. Weiner,et al.  Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment , 2011, Cancer Immunology, Immunotherapy.

[224]  C. Mandl,et al.  Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers , 2011, Proceedings of the National Academy of Sciences.

[225]  Jeffrey J. Gray,et al.  Analysis and Modeling of the Variable Region of Camelid Single-Domain Antibodies , 2011, The Journal of Immunology.

[226]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[227]  Qing-hui Zhou,et al.  Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. , 2011, Molecular pharmaceutics.

[228]  Henrik Næsted,et al.  Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use , 2011, Biotechnology and bioengineering.

[229]  I. Brukner,et al.  Host and pathogen factors for Clostridium difficile infection and colonization. , 2011, The New England journal of medicine.

[230]  P. Kaufmann,et al.  Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies. , 2011, Atherosclerosis.

[231]  Eva K. Lee,et al.  Systems Biology of Seasonal Influenza Vaccination in Humans , 2011, Nature Immunology.

[232]  Lila Adnane,et al.  Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9 , 2011, Molecular Cancer Therapeutics.

[233]  F. D. De Braud,et al.  A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma , 2011, Clinical Cancer Research.

[234]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[235]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[236]  C. Klein,et al.  Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 , 2011, Molecular Cancer Therapeutics.

[237]  D. Butler,et al.  Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments , 2011, PloS one.

[238]  J. Spratlin.  Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2 , 2011, Current oncology reports.

[239]  R. Kelley,et al.  High Affinity Antigen Recognition of the Dual Specific Variants of Herceptin Is Entropy-Driven in Spite of Structural Plasticity , 2011, PloS one.

[240]  J. Merchan,et al.  Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy , 2011, Molecular Cancer Therapeutics.

[241]  W. Ouwehand,et al.  Cross-domain inhibition of TACE ectodomain , 2011, Proceedings of the National Academy of Sciences.

[242]  Roland L. Dunbrack,et al.  A new clustering of antibody CDR loop conformations. , 2011, Journal of molecular biology.

[243]  M. Cragg,et al.  Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.

[244]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[245]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[246]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[247]  Stephen L. Hauser,et al.  Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation , 2011, Proceedings of the National Academy of Sciences.

[248]  J. Fitzgerald,et al.  Rational engineering of antibody therapeutics targeting multiple oncogene pathways , 2011, mAbs.

[249]  Benjamin D. Sellers,et al.  Effects of somatic mutations on CDR loop flexibility during affinity maturation , 2011, Proteins.

[250]  G. Henze,et al.  Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia , 2011, Leukemia.

[251]  Yoshihiro Kawaoka,et al.  Structure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus , 2011, Journal of Virology.

[252]  L. Kaltenbach,et al.  Perturbation with Intrabodies Reveals That Calpain Cleavage Is Required for Degradation of Huntingtin Exon 1 , 2011, PloS one.

[253]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[254]  P. S. Andersen,et al.  Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. , 2012, Blood.

[255]  D. Burton,et al.  Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2 , 2012, PloS one.

[256]  A. Casadevall,et al.  Variable Region Identical Immunoglobulins Differing in Isotype Express Different Paratopes* , 2012, The Journal of Biological Chemistry.

[257]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[258]  M. Nussenzweig,et al.  A mouse model for HIV-1 entry , 2012, Proceedings of the National Academy of Sciences.

[259]  J. Byrd,et al.  Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. , 2012, Blood.

[260]  T. Ghayur,et al.  Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. , 2012, Methods in enzymology.

[261]  Sean A Beausoleil,et al.  Proteomics-directed cloning of circulating antiviral human monoclonal antibodies , 2012, Nature Biotechnology.

[262]  D. Butler,et al.  Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies , 2012, mAbs.

[263]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[264]  W. Pardridge,et al.  Brain Protection from Stroke with Intravenous TNFα Decoy Receptor-Trojan Horse Fusion Protein , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[265]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[266]  S. Ansell,et al.  Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia , 2012, Clinical Cancer Research.

[267]  B. Kennedy,et al.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. , 2012, The Journal of infectious diseases.

[268]  Yu Zhou,et al.  Building and characterizing antibody-targeted lipidic nanotherapeutics. , 2012, Methods in enzymology.

[269]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[270]  K. Burke,et al.  Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates , 2012, Inflammatory bowel diseases.

[271]  James J. Campbell,et al.  Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells , 2012, Molecular Cancer Therapeutics.

[272]  F. White,et al.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. , 2011, Protein engineering, design & selection : PEDS.

[273]  Michael A. Stravs,et al.  Discovery of small-molecule interleukin-2 inhibitors from a DNA-encoded chemical library. , 2012, Chemistry.

[274]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[275]  Sean A Beausoleil,et al.  A proteomics approach for the identification and cloning of monoclonal antibodies from serum , 2012, Nature Biotechnology.

[276]  D. Butler,et al.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins , 2012, Progress in Neurobiology.

[277]  Q. Zeng,et al.  Awaiting a new era of cancer immunotherapy. , 2012, Cancer research.

[278]  W. Pardridge,et al.  Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. , 2012, Methods in enzymology.

[279]  B. Liu,et al.  Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study , 2012, Neurodegenerative Diseases.

[280]  E. Brunette,et al.  Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. , 2013, Molecular pharmaceutics.

[281]  G. Proetzel,et al.  IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society , 2013, mAbs.